Efficacy and safety of combined anlotinib-oral etoposide treatment for patients with platinum-resistant ovarian cancer
- Author:
Shuai HUANG
1
,
2
;
Guihua SHENG
;
Qiubo LV
;
Ye LI
;
Qingwei MENG
;
Xuexiao GAO
;
Zhiyuan SHANG
Author Information
- Publication Type:Original Article
- From:Journal of Gynecologic Oncology 2024;35(6):e100-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objective:Despite the availability of numerous treatment options, managing patients with platinum-resistant ovarian cancer (PROC) remains challenging, and the prognosis of PROC is notably unfavorable. This retrospective study aimed to assess the efficacy and safety of combined anlotinib-oral etoposide treatment for patients with PROC.
Methods:Data of 23 patients who were diagnosed with PROC from January 2020 to November 2022 and treated with anlotinib combined with oral etoposide for at least 2 cycles were retrospectively analyzed.
Results:Among per-protocol patients, 9 (45.0%; 95% confidence interval [CI]=21.1–68.9) of 20 patients achieved partial response and 17 (85.0%, 95% CI=67.9–100.0) of 20 patients achieved disease control. The median progression-free survival was 8.7 months (95% CI=5.3–11.6).The incidence of adverse events (any grade) was 100%, and the incidence of grade 3–4 adverse events was 54.5%.
Conclusion:Anlotinib combined with etoposide emerged effective for the treatment of PROC.
